Multimodality Management of Localized Biliary Cancer

Nadia Ashai, Preethi Prasad, Lakshmi Rajdev

Research output: Contribution to journalArticlepeer-review

4 Scopus citations


Biliary tract cancers (BTCs) are a diverse group of malignancies arising from the biliary tree, including cholangiocarcinoma and gallbladder carcinoma. Patients that are candidates for surgical resection should also have lymphadenectomy. Since recurrence rates are high, after surgical resection, patients should be considered for adjuvant therapy in a multidiscipline setting. The limited availability of randomized clinical trial data makes the optimal treatment option unclear; however, chemotherapy or chemoradiation has been shown to have benefits especially in patients with R1 or R2 resections or lymph node involvement. Patients with unresectable disease should be considered for neoadjuvant therapy with chemotherapy or chemoradiation. Patients that are unable to tolerate chemotherapy should also be considered for locoregional therapies. Clinical trial enrollment is strongly recommended for all patients. Trials involving targeted or immunotherapy are currently ongoing in patients with advanced disease.

Original languageEnglish (US)
Article number58
JournalCurrent treatment options in oncology
Issue number7
StatePublished - Jul 1 2019


  • Localized biliary cancer
  • Localized cholangiocarcinoma
  • Localized gallbladder cancer
  • Treatment localized biliary tract cancer
  • Treatment localized cholangiocarcinoma
  • Treatment localized gallbladder cancer

ASJC Scopus subject areas

  • Oncology
  • Pharmacology (medical)


Dive into the research topics of 'Multimodality Management of Localized Biliary Cancer'. Together they form a unique fingerprint.

Cite this